Price T Rowe Associates Inc Tarsus Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 239,315 shares of TARS stock, worth $12.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
239,315
Previous 291,275
17.84%
Holding current value
$12.7 Million
Previous $7.92 Million
0.58%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TARS
# of Institutions
170Shares Held
43.3MCall Options Held
484KPut Options Held
4.1K-
Rtw Investments, LP New York, NY3.41MShares$181 Million1.79% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$173 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$129 Million2.89% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$119 Million6.32% of portfolio
-
Morgan Stanley New York, NY2.21MShares$117 Million0.01% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.41B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...